Abstract:Background and Objective: Non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma viral oncogene homolog (KRAS) driver alterations harbors a poor prognosis with standard therapies, including chemotherapy and/or immunotherapy with anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) antibodies. Selective KRAS G12C inhibitors have been shown to provide significant clinical benefit in pretreated NSCLC patients with KRAS G12C mutation.Methods: In this review, we describe KRAS and the biology of KRAS-mutant tumors and review data from preclinical studies and clinical trials on KRAS-targeted therapies in NSCLC patients with KRAS G12C mutation.Key Content and Findings: KRAS is the most frequently mutated oncogene in human cancer. The G12C is the most common KRAS mutation found in NSCLC. Sotorasib is the first, selective KRAS G12C inhibitor to receive approval based on demonstration of significant clinical benefit and tolerable safety profile in previously treated, KRAS G12C-mutated NSCLC. Adagrasib, a highly selective covalent inhibitor of KRAS G12C, has also shown efficacy in pretreated patients and other novel KRAS inhibitors are being under evaluation in early-phase studies. Similarly to other oncogene-directed therapies, mechanisms of intrinsic and acquired resistance limiting the activity of these agents have been described.Conclusions: The discovery of selective KRAS G12C inhibitors has changed the therapeutic scenario of KRAS G12C-mutant NSCLC. Various studies testing KRAS inhibitors in different settings of disease, as single-agent or in combination with targeted agents for synthetic lethality and immunotherapy, are currently ongoing in this molecularly-defined subgroup of patients to further improve clinical outcomes.

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

Targeting KRAS in Non-Small Cell Lung Cancer

Resistance to KRAS inhibition in advanced non-small cell lung cancer

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Targeting KRAS in Colorectal Cancer

Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer

KRAS in NSCLC: State of the Art and Future Perspectives

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer